Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Skye Bioscience Inc (SKYE)

Skye Bioscience Inc (SKYE)
2.98 x 1 3.05 x 4
Post-market by (Cboe BZX)
2.98 -0.15 (-4.79%) 02/21/25 [NASDAQ]
2.98 x 1 3.05 x 4
Post-market 3.12 +0.14 (+4.70%) 16:46 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.93
Day High
3.27
Open 3.14
Previous Close 3.13 3.13
Volume 124,200 124,200
Avg Vol 225,945 225,945
Stochastic %K 35.76% 35.76%
Weighted Alpha -58.98 -58.98
5-Day Change -0.08 (-2.61%) -0.08 (-2.61%)
52-Week Range 2.31 - 19.41 2.31 - 19.41
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,407
  • Shares Outstanding, K 30,338
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,640 K
  • EBIT $ -24 M
  • EBITDA $ -23 M
  • 60-Month Beta 1.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.25

Options Overview Details

View History
  • Implied Volatility 270.58% ( -131.84%)
  • Historical Volatility 122.59%
  • IV Percentile 51%
  • IV Rank 33.87%
  • IV High 783.06% on 12/20/24
  • IV Low 8.06% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 1,581
  • Open Int (30-Day) 1,193

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 2
  • High Estimate -0.26
  • Low Estimate -0.34
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.36 +26.27%
on 01/23/25
Period Open: 2.70
4.25 -29.88%
on 01/31/25
+0.28 (+10.37%)
since 01/21/25
3-Month
2.31 +29.00%
on 12/30/24
Period Open: 4.17
4.60 -35.22%
on 11/29/24
-1.19 (-28.54%)
since 11/21/24
52-Week
2.31 +29.00%
on 12/30/24
Period Open: 6.25
19.41 -84.65%
on 03/04/24
-3.27 (-52.32%)
since 02/21/24

Most Recent Stories

More News
Skye Bioscience to Present at TD Cowen Health Care Conference

SKYE : 2.98 (-4.79%)
Skye Bioscience Announces Participation in February Conferences

SKYE : 2.98 (-4.79%)
Skye Bioscience Provides 2025 Look Ahead and Year in Review

SKYE : 2.98 (-4.79%)
Skye Bioscience to Present Corporate Overview at 43rd Annual J.P. Morgan Healthcare Conference

Skye Bioscience will present its corporate overview and Phase 2 trial results at the J.P. Morgan Healthcare conference.Quiver AI SummarySkye Bioscience, Inc. announced that it will present a corporate...

SKYE : 2.98 (-4.79%)
Skye Bioscience to Present at J.P. Morgan Healthcare Conference

SKYE : 2.98 (-4.79%)
Insider Sale: Chief Development Officer of $SKYE (SKYE) Sells 19,489 Shares

Tuan Tu Diep, the Chief Development Officer of $SKYE ($SKYE), sold 19,489 shares of the company on 11-18-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 19.2%...

SKYE : 2.98 (-4.79%)
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences

SKYE : 2.98 (-4.79%)
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

SKYE : 2.98 (-4.79%)
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

SKYE : 2.98 (-4.79%)
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

SKYE : 2.98 (-4.79%)

Business Summary

Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif.

See More

Key Turning Points

3rd Resistance Point 3.53
2nd Resistance Point 3.40
1st Resistance Point 3.19
Last Price 2.98
1st Support Level 2.85
2nd Support Level 2.72
3rd Support Level 2.51

See More

52-Week High 19.41
Fibonacci 61.8% 12.88
Fibonacci 50% 10.86
Fibonacci 38.2% 8.84
Last Price 2.98
52-Week Low 2.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements